← The Wire
MLTXNasdaq
MoonLake Immunotherapeutics
Pharmaceutical Preparations · E9 · CIK 1821586
Advancing novel therapies for inflammatory skin and joint diseases by developing a tri-specific IL-17 inhibitor
red 8-K · 90d
$1.38B
Market cap
$19.91
Last close
+0.1%
1D
-10.2%
5D
1.3M
Volume
Price · last 39 sessions+13.4%
May 4L $16.37 · H $22.16Jun 29
119
Total filings
Jun 25, 2026
Last filing
12/31
Fiscal year end
SC 13D/ASC 13D/AJun 29, 20268-KMaterial AgreementJun 25, 2026424B5PROSPECTUS SUPPLEMENTJun 24, 2026424B5PRELIMINARY PROSPECTUS SUPPLEMENTJun 22, 20268-KReg FD Disclosure · Company UpdateJun 22, 20268-KExecutive Change · Shareholder VoteJun 9, 20268-KMaterial AgreementJun 1, 202610-Q10-QMay 11, 20268-KResults of Operations · Reg FD DisclosureMay 11, 2026DEFA14ADEFA14AApr 21, 2026DEF 14ADEF 14AApr 21, 2026SC 13D/ASC 13D/AApr 2, 202610-K10-KFeb 25, 20268-KExecutive Change · Material AgreementFeb 23, 20268-KCompany UpdateJan 8, 20268-KMaterial AgreementNov 5, 2025424B5PROSPECTUS SUPPLEMENTNov 5, 202510-Q10-QNov 5, 20258-KResults of Operations · Reg FD DisclosureNov 5, 20258-KCompany UpdateSep 29, 202510-Q10-QAug 5, 20258-KResults of OperationsAug 5, 20258-KShareholder VoteJun 6, 202510-Q10-QMay 12, 20258-KResults of OperationsMay 12, 20258-KReg FD DisclosureApr 29, 2025DEFA14ADEFA14AApr 22, 2025DEF 14ADEF 14AApr 22, 20258-KMaterial Agreement · New Debt / ObligationApr 3, 202510-K10-KFeb 26, 20258-KResults of OperationsFeb 26, 20258-KExecutive ChangeDec 18, 202410-Q10-QNov 7, 20248-KResults of OperationsNov 7, 20248-KReg FD DisclosureSep 11, 202410-Q10-QAug 7, 20248-KResults of OperationsAug 7, 20248-KReg FD Disclosure · Company UpdateJun 10, 20248-KShareholder VoteJun 6, 202410-Q10-QMay 7, 20248-KResults of OperationsMay 7, 202410-K/A10-K/AMay 7, 2024DEFA14ADEFA14AApr 24, 2024DEF 14ADEF 14AApr 24, 20248-KReg FD Disclosure · Company UpdateMar 11, 202410-K10-KFeb 29, 20248-KResults of OperationsFeb 29, 20248-KReg FD DisclosureFeb 26, 2024SC 13GSC 13GFeb 9, 202410-Q10-QNov 14, 20238-KResults of OperationsNov 14, 20238-KReg FD Disclosure · Company UpdateNov 6, 20238-KReg FD DisclosureOct 16, 20238-KReg FD DisclosureSep 11, 20238-KExecutive ChangeSep 1, 202310-Q10-QAug 10, 20238-KResults of OperationsAug 10, 20238-KMaterial Agreement · Company UpdateJun 29, 2023424B5424B5Jun 29, 2023424B5424B5Jun 26, 20238-KReg FD DisclosureJun 26, 20238-KShareholder VoteJun 7, 20238-KExecutive ChangeMay 19, 2023424B5424B5May 11, 202310-Q10-QMay 11, 2023DEFA14AFORM DEFA14AApr 26, 2023DEF 14ADEF 14AApr 26, 20238-KReg FD DisclosureApr 19, 2023SC 13GSC 13GMar 31, 202310-K10-KMar 20, 20238-KResults of OperationsMar 20, 20238-KReg FD DisclosureMar 10, 202310-Q10-QNov 14, 202210-Q10-QAug 12, 2022SC 13GSC 13GAug 3, 2022S-1/AAMENDMENT NO. 5 TO FORM S-1Jul 26, 2022S-1/AREGISTRATION STATEMENTJul 15, 20228-KAuditor ChangeJun 17, 20228-KReg FD DisclosureJun 7, 20228-K/AAcquisition / DispositionMay 16, 2022
Insider Activity
In the 90 days to Dec 9, 2025: 1 insider bought $99K · 3 sold $52.9M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Dec 9, 2025 | Reich KristianChief Scientific Officer | Sell | 72,908 | $14.43 | $1.1M |
| Dec 9, 2025 | Santos Da Silva JorgeChief Executive Officer | Sell | 70,000 | $14.49 | $1.0M |
| Dec 8, 2025 | Santos Da Silva JorgeChief Executive Officer | Sell | 130,000 | $15.08 | $2.0M |
| Dec 8, 2025 | Reich KristianChief Scientific Officer | Sell | 130,000 | $15.08 | $2.0M |
| Oct 8, 2025 | Bodenstedt MatthiasChief Financial Officer | Buy | 10,870 | $9.09 | $99K |
| Sep 30, 2025 | Cormorant Global Healthcare Master Fund, LpOther | Sell | 5,827 | $6.96 | $41K |
| Sep 29, 2025 | Cormorant Global Healthcare Master Fund, LpOther | Sell | 3,390,943 | $7.58 | $25.7M |
| Sep 29, 2025 | Cormorant Global Healthcare Master Fund, LpOther | Sell | 2,800,000 | $6.61 | $18.5M |
| Sep 29, 2025 | Cormorant Global Healthcare Master Fund, LpOther | Sell | 232,460 | $8.40 | $2.0M |
| Sep 29, 2025 | Cormorant Global Healthcare Master Fund, LpOther | Sell | 70,748 | $9.38 | $664K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Similar companies
Comparable business profile · signals at a glance